New CEO Mark Bodmer nucleome.com/news-publicatio… “Nucleome have built a revolutionary technology which moves the field of genetics in medicine from its 1-D linear code to the interactions within its 3-D structure. It is a privilege to lead this ground-breaking company.”
Delighted to announce the appointment of Dr Mark Bodmer as CEO of Nucleome. nucleome.com/news-publicatio… Chair Dr Russell Grieg said: “Marks’s unusual combination of R&D and commercial expertise in driving great science will be crucial in delivering Nucleome’s continued development.”
Passionate about promoting inclusivity of diverse leadership styles, our CEO and Founder, @DM_Jeziorska, highlights how we can help empower female leaders in business.
Happy International Women’s Day! #iwd2024
This International Women’s Day, Danuta Jeziorska, CEO and Co-founder of @NucleomeTx, details how we can help empower female leaders in business 👇
#IWD2024 #FemaleFounders #Innovation #Entrepeneurship
@UniofOxford @enspireoxford

ALT The prevalent cultural understanding of what a strong leader looks like is heavily masculinised. This needs to be redefined such that people understand what strong female leaders look like on their own terms, for example by celebrating and highlighting the features of women that make them great leaders. We need to embrace vulnerability, empathy, and compassion as pillars of strength. By reshaping the narrative of what it means to be a leader, we will promote inclusivity of diverse leadership styles.
Our CEO & Founder, @DM_Jeziorska, is featured in the latest instalment of @PharmaScrip #ScripAsks series by @ScripEleanor on the transformative technologies poised to shape 2024.
👉 You can read the article here: lnkd.in/dWeM2Bcy
#2024Predictions #DarkGenome #Genomics
Join us to decode the genetics located in the #darkgenome to discover & develop #precisionmedicine.
We're currently recruiting for 3 pivotal roles: 2 Snr Scientists & Scientist in #FunctionalGenomics.
To apply: nucleome.com/careers/
#Genomics #GeneRegulation #3Dgenome #Oxford
Our CEO & Co-founder @DM_Jeziorska,
Co-Founder Jim Hughes,
CBO Nigel Clark, &
CSO Steve Harrison, will be attending the JP Morgan Healthcare Conference in San Francisco, 08-11 January 2024.
We are looking forward to meeting with potential partners & collaborators.
#JPM2024
As we closed 2023, our CEO & Founder Danuta Jeziorska reflected on the milestones the Company has achieved:
linkedin.com/posts/nucleome-…
We’ve been spotlighted in two recent industry features!
UKT News’ Which UK Genetics Startups are Revolutionising Biotechnology in 2023? lnkd.in/eWnmcBYX
AlbionVC’s 2023 European HealthTech Market Map in the category of Digital Pharma - Tech Bio
lnkd.in/e4BAJtf6
🔦 Genetics Unzipped – Afraid of the dark?
Our CEO & Founder @DM_Jeziorska is a guest on the latest episode of #genetics Unzipped with Kat Arney, which is now online and ready for you to tune in!
👉 You can listen to the podcast here: geneticsunzipped.com/blog/20…
We are excited to share that the appointment of our new Chief Scientific Officer, Stephen Harrison, has been featured in @BioCentury
Read the full article here: biocentury.com/article/65066…
#Appointment #Genomics #DarkGenome #DrugDiscovery #PrecisionMedicine
We are excited to welcome Dr. Stephen Harrison to Nucleome Therapeutics as our Chief Scientific Officer, bringing 30 years of drug discovery and development expertise as the Company continues to build a portfolio of first-in-class targets.
lnkd.in/e5rjdgkH
The #DarkGenome Symposium starts today, and we are delighted that leaders from across academia, biotech, pharma, and investment gathered to discuss the latest advancement in the Dark Genome field and their translation to precision medicine.
Our CEO @DM_Jeziorska spoke to @OxUInnovation about the pioneering work we do at Nucleome Therapeutics and being part of Oxford’s thriving life sciences innovation scene.
Read the full article here: innovation.ox.ac.uk/news/oxf…
#Oxford #Biotech #DarkGenome #Genomics
Delighted that Nucleome is showcased as one of the 50 companies in @PwC_UK’s 'Life Sciences Future 50' report, illustrating the world-class science and innovation being led by the UK’s life sciences sector.
Read the report here: bit.ly/3Fnw379
Nucleome has been shortlisted in the Biotech of the Year category at the European @lifestarsawards – a testament to our commitment to decoding the dark matter of the human genome to develop first-in-class precision medicines.
@NucleomeTx has been featured in a new @BioCentury. Emerging Company Profile by Karen Tkach Tuzman
The article discusses the dark genome, Nucleome’s innovative 3D genome methods, our origins, as well as an interview with our CEO @DM_Jeziorska
biocentury.com/article/64895…
Our CEO @DM_Jeziorska is interviewed as part of @creativedlab Oxford new article celebrating that startups from the Oxford Creative Destruction Lab programme, based in the @SBSInsights @UniofOxford have collectively created a record £1.3bn in equity value!
lnkd.in/eSHZmnUU
Call for Abstracts
@NucleomeTx @Enara_Bio & @rome_tx are delighted to be hosting the 2nd Annual #DarkGenome Symposium at @TheCrick #London on 13-14 Nov 2023.
We welcome submission of all abstracts covering Dark Genome science. lnkd.in/ev9ptNEz
Abstracts should not exceed 250 words, and the first/lead author will present the poster for selected abstracts.
Please submit abstracts to [email protected] by 13 October. Selected abstract authors will be notified by 20 October.
Great to see Dr Russell Greig's appointment as Non-Executive Chair of Nucleome Therapeutics featured in @BioCentury.
biocentury.com/article/64919…
#genomics #darkgenome #biotech #appointment










